X

Drug Profile

Research programme: anti-influenza vaccines - SK bioscience/ The Peter Doherty Institute for Infection and Immunity

Latest Information Update: 25 Aug 2023

Price : $50 ^*

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator SK Bioscience; The Peter Doherty Institute for Infection and Immunity
Class Antivirals; Immunotherapies; Influenza virus vaccines; Subunit vaccines
Mechanism of Action Immunostimulants

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Highest Development Phases

Research Influenza virus infections

Most Recent Events

27 Jun 2023 Sk bioscience and The Peter Doherty Institute for Infection and Immunity both enters into a collaboration to co-develop quadrivalent cell culture-based influenza vaccine
27 Jun 2023 Early research in Influenza virus infections in South Korea (Parenteral)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com